Abstract
Dementia caused by Alzheimers disease is a large medical burden on society in the developed world. Current treatments are largely symptomatic, and there is an urgent need for therapies which can interrupt or reverse the progression of disease. A number of strategies for intervention are being actively pursued; among the most promising is the inhibition of β-secretase, or BACE. BACE is the enzyme responsible for N-terminal cleavage of the Alzheimers precursor protein leading to the production of the beta-amyloid peptide. This cascade ultimately leads to the formation of amyloid plaques, one of the hallmark lesions of the disease. It is expected that inhibitors of BACE may therefore serve as an effective disease-modifing therapy for the treatment of AD. This concept has received significant attention by both academics and the pharmaceutical industry. This review focuses on a discussion of the reported structure-activity relationships for inhibitors of this important therapeutic target.
Keywords: alzheimers disease, statines, hydroxymethylcarbonyl isosteres, azabicyclononane hiv protease, piperazine inhibitors, macrocycles
Current Pharmaceutical Design
Title: Progress in the Discovery of BACE Inhibitors
Volume: 11 Issue: 26
Author(s): L. A. Thompson, J. J. Bronson and F. C. Zusi
Affiliation:
Keywords: alzheimers disease, statines, hydroxymethylcarbonyl isosteres, azabicyclononane hiv protease, piperazine inhibitors, macrocycles
Abstract: Dementia caused by Alzheimers disease is a large medical burden on society in the developed world. Current treatments are largely symptomatic, and there is an urgent need for therapies which can interrupt or reverse the progression of disease. A number of strategies for intervention are being actively pursued; among the most promising is the inhibition of β-secretase, or BACE. BACE is the enzyme responsible for N-terminal cleavage of the Alzheimers precursor protein leading to the production of the beta-amyloid peptide. This cascade ultimately leads to the formation of amyloid plaques, one of the hallmark lesions of the disease. It is expected that inhibitors of BACE may therefore serve as an effective disease-modifing therapy for the treatment of AD. This concept has received significant attention by both academics and the pharmaceutical industry. This review focuses on a discussion of the reported structure-activity relationships for inhibitors of this important therapeutic target.
Export Options
About this article
Cite this article as:
Thompson A. L., Bronson J. J. and Zusi C. F., Progress in the Discovery of BACE Inhibitors, Current Pharmaceutical Design 2005; 11 (26) . https://dx.doi.org/10.2174/138161205774370825
DOI https://dx.doi.org/10.2174/138161205774370825 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Dehydroepiandrosterone (DHEA) and its Sulphate (DHEAS) in Alzheimer’s Disease
Current Alzheimer Research Does the Cholinesterase Inhibitor, Donepezil, Benefit Both Declarative and Non-Declarative Processes in Mild to Moderate Alzheimers Disease?
Current Alzheimer Research Oral Health in Alzheimers Disease: A Review
Current Alzheimer Research The Impact of the Induction of Multidrug Resistance Transporters in Therapies by Used Drugs: Recent Studies
Mini-Reviews in Medicinal Chemistry Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities
Current Neuropharmacology An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Alzheimer Research Investigating Physical, Psychological and Social Well-being of Older Persons in Jordan
Current Aging Science Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death
Current Neuropharmacology Metformin Eased Cognitive Impairment Induced by Chronic L-methionine Administration: Potential Role of Oxidative Stress
Current Neuropharmacology Apolipoprotein E Gene Revisited: Contribution of Rare Variants to Alzheimer’s Disease Susceptibility in Southern Chinese
Current Alzheimer Research A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Amino-Alkyl-Cyclohexanes as a Novel Class of Uncompetitive NMDA Receptor Antagonists
Current Pharmaceutical Design Inflammatory Biomarkers in AD: Implications for Diagnosis
Current Alzheimer Research Cardiovascular Drugs and Bone
Current Drug Safety Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design